YOLFTbeta
31

Medigen Biotechnology

3176 · TWO · Healthcare / Biotechnology

30.75TWD+0.45 (+1.49%)

Price History

Full chart

Market Stats

Previous Close30.30
Open30.80
Day Range30.50 – 31.25
52-Week Range28.00 – 43.60
Volume147.64K
Market Cap5.23B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.81
Dividend Yield0.00%
Beta0.31
50-Day Avg35.69
200-Day Avg33.45

About

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for head and neck cancer, and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1990 and is headquartered in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Shi-Chung Chang M.D., Ph.D.
  • Employees0
  • HeadquartersNo.3, Park Street, Taipei, Taiwan, 115603, Taiwan
  • Websitehttps://www.medigen.com.tw

Leadership

  • Dr. Shi-Chung Chang M.D., Ph.D.Chairman & President · b. 1959
  • Ms. Feng-Hua ChenFinance Manager & Accounting Officer
  • Ms. Ya-Ling ChiangAssistant Vice President of Operations & Management Department
  • Ms. Chin-Yen ChenAssistant Vice President of Drug Development Department
  • Mr. Shun-Lang ChangGeneral Manager

Financials

Income Statement

Currency: TWD2003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue44.10M6.62M20.00M963.00K8.43M38.97M34.43M70.51M113.71M110.00M72.98M371.83M363.00M399.89M427.48M407.31M552.35M614.18M3.92B1.06B1.16B1.37B1.58B
Growth (%)--85.00%+202.34%-95.19%+775.39%+362.30%-11.65%+104.77%+61.27%-3.26%-33.66%+409.50%-2.37%+10.16%+6.90%-4.72%+35.61%+11.19%+538.80%-73.09%+9.64%+18.57%+15.28%
Cost of Revenue----133.57M2.53M4.29M2.77M21.18M762.49M32.78M187.03M271.76M345.73M339.56M327.61M331.20M385.94M1.39B982.88M640.62M618.94M677.48M
Gross Profit------------91.24M54.17M87.91M79.69M221.15M228.24M2.53B73.07M517.10M753.76M905.02M
Gross Margin------------25.13%13.55%20.57%19.57%40.04%37.16%64.59%6.92%44.67%54.91%57.19%
Operating Expense------------843.13M804.50M734.43M842.11M983.47M1.14B1.75B1.74B1.75B964.48M1.01B
Operating Income-------------751.88M-750.33M-646.52M-762.42M-762.33M-912.17M789.20M-1.67B-1.23B-210.72M-105.03M
Operating Margin-------------207.13%-187.63%-151.24%-187.19%-138.02%-148.52%20.12%-157.87%-106.51%-15.35%-6.64%
EBITDA--------------591.18M-429.63M-550.55M-548.88M-693.33M987.63M-1.48B-1.05B98.91M-19.84M
EBITDA Margin--------------147.83%-100.50%-135.17%-99.37%-112.89%25.17%-139.72%-91.10%7.21%-1.25%
Net Income----187.23M44.18M---416.40M---540.93M-568.31M-466.75M-442.67M-255.72M-337.92M-52.61M-675.87M-561.30M-204.69M-108.80M
Net Income Margin----2221.02%113.36%---378.54%---149.01%-142.12%-109.19%-108.68%-46.30%-55.02%-1.34%-64.01%-48.48%-14.91%-6.88%
R&D91.62M115.23M79.39M85.62M38.15M38.83M42.22M72.69M198.43M302.50M507.13M613.62M556.73M431.23M450.42M551.87M664.24M803.37M1.38B1.32B1.33B393.27M451.90M
R&D as % of Total Revenue207.76%1741.93%396.97%8890.76%452.50%99.63%122.60%103.10%174.50%275.00%694.89%165.03%153.37%107.84%105.37%135.49%120.26%130.80%35.07%124.88%114.75%28.65%28.56%
Interest Expense000000000000010.86M19.20M23.12M31.59M31.88M19.07M39.45M55.86M36.39M23.12M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%2.71%4.49%5.68%5.72%5.19%0.49%3.74%4.82%2.65%1.46%

Balance Sheet

Currency: TWD2003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets966.81M767.53M702.17M742.89M593.03M680.98M679.27M869.78M1.21B2.24B3.29B4.46B4.49B4.82B4.87B4.60B4.83B6.15B8.20B9.98B8.53B6.71B6.18B
Total Liabilities110.16M28.26M51.78M74.96M124.35M141.33M82.25M61.88M298.81M186.42M226.84M804.40M1.03B1.28B1.69B1.66B2.14B1.65B1.77B3.51B3.53B1.67B1.46B
Total Equity856.65M739.26M650.39M655.46M452.76M511.65M565.29M774.80M883.24M1.99B2.83B2.89B2.49B2.20B1.84B1.54B1.36B1.82B2.39B2.19B1.59B1.58B1.55B
Cash51.26M41.79M103.27M89.10M144.45M185.43M116.34M183.80M498.32M599.07M1.05B800.61M1.17B970.74M1.17B590.76M813.69M2.21B2.14B2.04B2.22B1.39B1.32B
Total Debt-------------1.10B1.43B1.39B1.76B1.20B1.04B2.81B2.91B--
Net Debt-------------133.40M258.85M801.80M944.33M-1.00B-1.11B768.60M688.74M--

Cash Flow

Currency: TWD2003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow445.46M-80.72M---------294.18M-468.61M-455.62M-529.82M-560.17M-671.38M517.45M-1.13B-569.40M37.92M40.55M
Investing Cash Flow-106.11M-43.29M60.99M-8.32M--269.29M---517.12M-258.79M-114.77M-672.53M446.53M-237.09M-910.50M----
Financing Cash Flow100.00M-22.00M44.40M59.64M163.72M107.59M329.09M481.49M772.21M1.49B599.05M604.65M272.82M327.52M1.13M66.40M-33.45M-209.29M1.72B35.14M--
Capital Expenditure3.96M689.00K3.21M7.88M5.08M79.56M19.47M46.42M30.52M218.12M218.17M622.15M515.25M566.22M110.73M124.13M113.85M140.29M144.55M151.37M50.92M58.68M73.43M
Free Cash Flow--------------1.03B-566.36M-653.94M-674.01M-811.67M372.90M-1.28B-620.32M-20.76M-32.88M
Dividends Paid-------------------30.04M37.55M54.19M57.80M
FCF to OCF-------------220.83%124.30%123.43%120.32%120.90%72.07%113.42%108.94%-54.74%-81.10%
Dividend Paid to FCF--------------------2.35%-6.05%-261.07%-175.77%

Earnings

Report DateApr 15, 2012Aug 30, 2012Mar 27, 2013Aug 14, 2013Nov 14, 2013Mar 31, 2014Aug 14, 2014Nov 14, 2014May 15, 2015
EPS Estimate-0.39-0.39-0.57-0.53-0.57-0.60-0.80-0.96-0.87
EPS Actual-0.34-0.683.47-0.68-0.82-1.01-0.90-2.27-1.04
Surprise12.82%-74.36%708.77%-28.30%-43.86%-68.33%-12.50%-136.46%-19.54%
TimingAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap5.23B
Enterprise Value4.34B
Trailing P/E0.00
Forward P/E0.00
Price / Sales4.12
Price / Book3.64
EPS-1.81
Book Value10.60
Revenue (TTM)1.27B
Gross Profit (TTM)657.17M
EBITDA-93.97M
Profit Margin-19.89%
Operating Margin6.94%
Return on Equity-7.45%
Return on Assets-2.27%
Shares Outstanding139.31M
Shares Float109.21M
Beta0.31
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%